Introduction {#s1}
============

Urinary tract infections (UTIs) are one of the most common bacterial infections. UTI is especially common in women as nearly half of all women will be infected during their lifetime (Foxman, [@B14]). The vast majority of all urinary tract infections are caused by uropathogenic *Escherichia coli* (UPEC), accounting for approximately 80% of community-acquired symptomatic UTI and approximately 25% of the nosocomial infections (Ronald, [@B29]). UPEC isolates have been shown to express an array of virulence factors like adhesins (such as P- and type-1 fimbriae), toxins (α-hemolysin), lipopolysaccharide (LPS), capsular, siderophores (iron scavenger system) and TcpC to evade the host defenses and colonize the urinary tract (Bower et al., [@B5]; Yadav et al., [@B38]).

During UTI, UPEC may invade the urothelial cells where they can replicate and form biofilm-like intracellular bacterial communities (IBCs) (Anderson et al., [@B2]). Likewise, after the resolution of an active infection non-replicating bacteria can remain within vesicles in deeper layers of the urothelium as quiescent intracellular reservoirs (QIRs) (Mysorekar and Hultgren, [@B25]). These QIRs can remain quiescent for several months without eliciting an inflammatory response. The intracellular niche not only protects the bacteria from many of the innate immune defenses, such as phagocytosis by neutrophils (Justice et al., [@B19]), but also from antibiotics that often are ineffective in eliminating intracellular bacteria (Blango and Mulvey, [@B3]). The subsequent resurgence of these intracellular reservoirs can be the cause of recurrent or chronic UTI (Rosen et al., [@B31]). UPEC exhibit morphological plasticity within the IBCs (Justice et al., [@B19], [@B20]; Horvath et al., [@B18]). In the initial phase, bacteria transform from a rod shape to coccoid morphology that may follow by an additional transition into a filamentous form (Justice et al., [@B19]; Horvath et al., [@B18]). As bacteria emerge from the IBC they may do so in a filamentous form (Justice et al., [@B19]). Filamentous *E. coli* have been observed in urine from women with UTI and the filamentation *per se* may serve as a strategy to resist host immune responses, such as phagocytosis (Horvath et al., [@B18]), but may also be seen as a more general stress response. Filamentation can be induced by components of an activated host defense system (Justice et al., [@B20]), shear stress (Khandige et al., [@B21]) and also in response to treatment with different beta-lactam antibiotics, in particular, aminothiazolyl cephalosporins like ceftibuten. Beta-lactam antibiotics induce *E. coli* filamentation by inhibiting penicillin-binding protein-3 (PBP-3) that catalyzes septa formation (Gould and MacKenzie, [@B17]). SulA, a member of the bacterial SOS DNA damage repair system, has also been shown to induce bacterial filamentation. It was recently shown that cell division gene *damX* is also a mediator of reversible filamentation of UPEC (Khandige et al., [@B21]). We have previously shown that filamentation of extended spectrum β-lactamase (ESBL)-producing UPEC isolates can alter the ability of UPEC to evoke pro-inflammatory responses in renal epithelial cells and neutrophils (Demirel et al., [@B12]). Therefore, knowledge of the virulence factors expressed by different morphological forms of UPEC may be used to devise novel therapeutic strategies to obstruct these virulence factors in order to inhibit pathogenesis.

A major concern and emerging health problem is the increasing incidence of antibiotic resistance among uropathogenic strains (Coque et al., [@B11]; Brolund, [@B7]). A majority of the ESBL-producing bacteria are isolated from urine samples (Pitout and Laupland, [@B28]; Khanfar et al., [@B22]). In addition, mortality has been shown to increase in ESBL-induced infections proportionally with the duration of the delay in effective treatment, making the choice of correct antibiotics critical for patients (Tumbarello et al., [@B36]).

The virulence capacity of ESBL-producing UPECs during their morphological shifts remains to be properly studied. The aim of the present study was to investigate changes in global gene expression patterns and in virulence factor-associated genes in ESBL-producing UPEC during the morphologic transitions induced by ineffective antibiotics in the presence of human primary bladder epithelial cells.

Material and methods {#s2}
====================

Cell and bacterial culture
--------------------------

Primary human bladder epithelium progenitor cells (HBEP, CELLnTEC Advanced Cell Systems AG, Bern, Switzerland) were cultured in wells with CnT-58 cell culture medium (CELLnTEC) supplemented with 100 U/mL penicillin and 100 μL/mg streptomycin (both from Invitrogen Ltd, Paisley, UK) in a humidified atmosphere with 5% CO~2~ at 37°C. At confluency the culture was differentiated during 4 days using CnT-21 differentiation medium (CELLnTEC) supplemented with 1 mM CaCl~2~. The ESBL-producing UPEC was originally isolated from a patient at Örebro University hospital, Sweden. The isolate, designated ESBL019 (previously named ESBL7, Demirel et al., [@B12]), has previously been characterized and determined to be multidrug resistant (CTX-M-15) and resistant to ceftibuten (MIC 7,680 ng/ml) and belongs to the ST131 clone (Onnberg et al., [@B26]). ESBL019 was grown in Luria broth (Difco Laboratories, Detroit, MI, USA) overnight on shake at 200 rpm 37°C. The bacteria were resuspended in sterile phosphate buffered saline prior to inoculation of CnT-21 cell culture medium (CCM) with or without ceftibuten (480 ng/mL). The antibiotic concentration used is a reference minimal inhibitory concentration (MIC) of ceftibuten that was determined on two antibiotic susceptible UPEC isolates as previously defined (Demirel et al., [@B12]).

Morphologic transitions and evaluation
--------------------------------------

Four morphologic states of ESBL019 were used during the experiments (Figure [1](#F1){ref-type="fig"}). A first ESBL019 morphological state was prepared by resuspension of ESBL019 in CCM without ceftibuten supplementation prior to its inoculation of HBEP cells without ceftibuten (designated; ESBL019 Coliform). A second ESBL019 morphological state was prepared by resuspension in CCM and then used to inoculate HBEP cells with ceftibuten supplementation (480 ng/mL) (designated; ESBL019 Transition). This transition from coliform into filamented occurs in the presence of HBEP cells. A third ESBL019 morphological state was prepared by resuspension and pre-incubation for 3 h in CCM with ceftibuten in a tube, in order to induce complete filamentation of all bacteria. Filamentation was confirmed by microscopy. The third pre-filamented ESBL019 fraction was used to inoculate HBEP cells in the presence of ceftibuten to keep the bacteria filamented (designated; ESBL019 Filamented). The CCM of the pre-filamented ESBL019 fraction was replaced with CCM without ceftibuten and the filamented ESBL019 were allowed to revert completely back to its coliform during 1 h in a tube prior to the inoculation of HBEP cells without ceftibuten (designated; ESBL019 Reverted) (Figure [1](#F1){ref-type="fig"}). The bacterial morphologies were evaluated with an Olympus CKX41 inverted light microscope (Olympus, Segrate, Italy). Prior to inoculation the bacterial concentrations of all fractions were adjusted in order to inoculate HBEP cells with a multiplicity of infection (MOI) of 10. All inoculated cells were incubated for 4 h in 5% CO~2~ at 37°C after which supernatants were collected and centrifuged 5 min at 5,000 × g to collect the extracellular bacteria. The viability of the HBEP cells was \>90% after the infection as determined by the neutral red assay. The HBEP cells were then lysed with sterile MQ water for 3 min and the intracellular bacteria were collected and centrifuged for 5 min at 5,000 × g followed by a washing step with PBS.

![Summary of the experimental design, morphological transition and visual evaluation by light microscope of the different forms of ESBL019. Scale bar: 100 μm.](fmicb-08-01058-g0001){#F1}

RNA preparation and microarray
------------------------------

Total RNA was isolated from the combined intra-and extracellular bacteria with the RNeasy Mini Kit (Qiagen Technologies, Hilden, Germany) according to manufacturer instructions. Contaminating DNA was removed by DNase digestion (TURBO DNase, Life technologies, MA, USA) according to manufacturer instructions. RNA concentration and purity were determined using a Nano-Drop ND-1000 Spectrophotometer (Nano-Drop Technology Inc., Wilmington, DE, USA). All samples had OD260/280 and OD260/230 ratios above 1.9. RNA quality was further evaluated using Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) according to manufacturer instructions. All samples had RNA integrity number (RIN) values above 9. High-quality total RNA from four biological replicates was used to prepare labeled cRNA with Low Input Quick Amp WT Labeling Kits (Agilent) according to manufacturer instructions. Labeled cRNA samples were hybridized in a G2545A hybridization oven (Agilent) onto Agilent SurePrint G3 *E. coli* Gene Expression 8x15k (Agilent Technologies) glass arrays according to manufacturer instructions and subsequently scanned with a G2565 CA array laser scanner (Agilent Technologies). Image analysis and data extraction was performed with Feature Extraction Software (version 10.7.3.1, Agilent Technologies). The virulence factor list for *E. coli* was generated through the use of virulence association in the PATRIC database ([www.patricbrc.org](http://www.patricbrc.org)) with the addition of MESH virulence search term associated genes and literature mining. Gene expression data is available in the GEO database with the accession number [GSE99661](GSE99661).

Quantitative real-time PCR (qPCR)
---------------------------------

cDNA synthesis (200 ng of total RNA) was performed by using High Capacity cDNA Reverse Transcription Kit for single-stranded cDNA synthesis (Applied Biosystems, CA, USA) according to manufacturer's protocol. Maxima SYBR Green qPCR Master Mix (ThermoFisher Scientific, MA, USA) was used for the qPCR according to manufacturer\'s instructions. Two hundred and fifty nanometer of primer and 10 ng template cDNA was added to each reaction. Primers were ordered from Eurofins MWG Synthesis GmbH (Ebersberg, Munich, Germany) (Table [S1](#SM1){ref-type="supplementary-material"}). The amplification was performed in a CFX96 Touch™ Real-Time PCR Detection System (Biorad, CA, USA) using the following protocol: initial denaturation at 95°C for 10 min, 40 cycles of denaturation at 95°C for 15 s followed by annealing at 60°C for 30 s and extension at 72°C for 30 s. The PCR was followed by a dissociation curve analysis between 60 and 95°C. The Ct values were analyzed by the comparative Ct (ΔΔCt) method and normalized to the endogenous control gapA (encoding glyceraldehyde 3-phosphate dehydrogenase A). Fold difference was calculated as 2^−ΔΔCt^.

Transmission electron microscopy
--------------------------------

ESBL019 was prepared for electron microscopy with or without ceftibuten as previously mentioned, but without the presence of HBEP cells. ESBL019 was washed in PBS before fixation with 5% glutaraldehyde in 0.1 M phosphate buffer. The bacteria were absorbed on carbon-coated copper grids and contrasted with 1% uranyl acetate solution. A JEOL JEM 1230 transmission electron microscope at 80-kV accelerating voltage was used for examination and images were recorded with a Gatan Multiscan 791 CCD camera.

Agglutination assays
--------------------

ESBL019 in its four different morphological states were collected after HBEP inoculation to measure Type-1-and P-fimbriae phenotype expression. The expression of Type-1 fimbriae was evaluated using 5% yeast diluted in PBS and the expression of P-fimbriae was evaluated using 2% of P-positive human erythrocytes diluted in PBS. All the bacteria from the well were mixed 1:1 (v/v) with yeast or erythrocytes on a glass slide and agglutination was evaluated with an Olympus CKX41 inverted light microscope.

Measurement of TNF-α release from primary bladder epithelial cells
------------------------------------------------------------------

An enzyme-linked immunosorbent assay (ELISA) was performed to measure the TNF-α release from HBEP cells in response to the different morphological states of ESBL019. TNF-α was measured using the human TNF-α kit (ELISA MAX™ Standard, BioLegend, San Diego, CA, USA) according to the manufacturer\'s protocol and measured on a spectrophotometer (Multiskan Ascent, Thermo Labsystems, Helsingfors, Finland).

Statistical analysis and microarray data processing
---------------------------------------------------

All microarray data analysis was performed using Gene Spring GX version 13.0 (Agilent Technologies) after per chip and gene 75th percentile shift normalization of samples. Different expression between groups was analyzed with one-way analysis of variance (ANOVA) parametric test. Significantly expressed entities (*p* \< 0.05) was obtained by Tukey HSD *post hoc* test followed by Bonferroni multiple testing correction and a fold change set at ≥2. Significance for GO term enrichment and single experiment pathway analysis were set at a *p*-value \< 0.05 and *p*-value \< 0.1 respectively. The virulence factor list for *E. coli* was generated through the use of virulence association in the PATRIC database ([www.patricbrc.org](http://www.patricbrc.org)) with the addition of MESH virulence search term associated genes and literature mining. In total the list was composed of 305 genes classified as associated with or designated to virulence. The differences between groups in the ELISA assay were evaluated with one-way ANOVA followed by Bonferroni test. The differences compared to ESBL019 Coliform in the qPCR were evaluated with Student\'s unpaired *t*-test. Differences were considered statistically significant when *p* \< 0.05. Data are presented as mean ± standard error of the mean (SEM), *n* = number of independent experiments.

Results {#s3}
=======

Morphological plasticity of *E. coli* in response to ceftibuten exposure
------------------------------------------------------------------------

ESBL019 is a strain resistant to ceftibuten. It changed morphology from its normal coliform into a filamentous form (\>100 μm) after exposure to ceftibuten in the presence of human primary bladder epithelial cells (HBEP). This transition in the presence of HBEP is defined as ESBL019 Transition. The filamentation process started as early as 1 h after the addition of ceftibuten and the bacteria reached full filamentation approximately 3 h after exposure to ceftibuten. After removing ceftibuten from the growth medium, the filamentous ESBL019 reverted completely back to its coliform within 1 h (Figure [1](#F1){ref-type="fig"}). Transmission electron microscopy showed a normal Coliformed bacteria (Figure [2A](#F2){ref-type="fig"}) and that the septa between the bacteria was not fully formed in the filamented phase (Figure [2B](#F2){ref-type="fig"}). The reversion from the filamentous form back to the coliform was associated with formation of the bacterial septa (Figures [2C,D](#F2){ref-type="fig"}).

![Visual evaluation of the different forms of ESBL019 by transmission electron microscope. ESBL019 Coliform **(A)** was grown for 3 h without ceftibuten, ESBL019 Filamented **(B)** was grown for 3 h in the presence of ceftibuten and ESBL019 Reverted **(C,D)** was grown in the presence of ceftibuten for the first 3 h and then without for 1 h to allowed the bacteria to revert completely back to its coliform. Septa formation during reversion can also be observed **(C)**. Scale bar: 0.5 μm **(A,C,D)** 2 μm **(B)**.](fmicb-08-01058-g0002){#F2}

Gene expression alterations in the different morphological phases
-----------------------------------------------------------------

Microarray analysis was performed on total RNA isolated from (intra and extracellular) bacteria prior to and following their morphological transition from coliform to filamentous form and then reverted to their original coliform. In total 6438 entities were differentially expressed (*p* \< 0.05) with at least a ≥2 fold change compared to the ESBL019 Coliform. All three morphological states, ESBL019 Transition, ESBL019 Filamented and ESBL019 Reverted, induced changes in gene expressions with 683, 3,720, and 1,951 up-regulated and 283, 1,026, and 827 down-regulated gene expressions, respectively (Figure [3](#F3){ref-type="fig"}). A total of 739 altered gene entities are shared between ESBL019 Transition and ESBL019 Filamented with 585 up-regulated and 157 down-regulated entities, and 1,239 gene entities were shared between ESBL019 Filamented and ESBL019 Reverted with 914 up-regulated and 325 down-regulated entities. In addition, 381 shared gene entities were differentially expressed in all three groups (Figure [3](#F3){ref-type="fig"}).

![Venn diagram of differentially expresses entities. Red represents ESBL019 Transition compared to ESBL019 Coliform, blue represents E7 Filamented compared to ESBL019 Coliform and green represents ESBL019 Reverted compared to E7 Coliform. Overlapping regions represents shared entities. Up- and down-regulated entities are designated U and D respectively. *n* = 4 per group.](fmicb-08-01058-g0003){#F3}

Gene ontology and pathway analysis
----------------------------------

Gene ontology (GO) analysis was performed on significantly altered gene entities compared to ESBL019 Coliform expression. In total, 14 (ESBL019 Transition), 9 (ESBL019 Filamented) and 4 (ESBL019 Reverted) gene ontologies were uniquely enriched (Table [S2](#SM2){ref-type="supplementary-material"}). Single experiment pathway analysis (SEA) (*p* \< 0.05) was performed in order to determine significantly affected cellular pathways. In total, 33 pathways were altered, of which 30 pathways were related to metabolism and the rest to enterobactin biosynthesis and polymyxin resistance (Table [S3](#SM3){ref-type="supplementary-material"}).

Virulence factors in the different morphological states
-------------------------------------------------------

Next, a more detailed analysis of the alterations in expression patterns of virulence associated genes of ESBL019 was conducted. The compiled list of virulence factor associated genes, 305 entities in total, was used to filter out significantly altered entities associated with virulence in the different groups. In total, 199 altered gene entities were identified with association to virulence. These 199 altered gene entities were grouped into 10 different functional groups; Adhesion, Growth, LPS synthesis, Metabolism, Motility, Protection, Siderophore, Toxins, Secretion and Transcription regulation. Of the 199 genes, 19 genes had significantly altered expressions in all three morphological states compared to the original ESBL019 Coliform (Table [1A](#T1){ref-type="table"}). The ESBL019 Transition state showed altered expression of 33 virulence associated genes (Tables [1A](#T1){ref-type="table"},[B](#T2){ref-type="table"}). The ESBL019 Filamented state showed the single largest alteration in virulence associated gene expression. A total of 149 altered expression in genes was observed in the ESBL019 Filamented state (Tables [1A](#T1){ref-type="table"},[B](#T2){ref-type="table"}). The ESBL019 Reverted state showed altered expression of 92 virulence associated genes (Tables [1A](#T1){ref-type="table"},[B](#T2){ref-type="table"}).

###### 

Shared virulence factors associated genes present among significantly altered entities in ESBL019 Transition, ESBL019 Filamented and ESBL019 Reverted compared to ESBL019 Coliform.

  **Function**    **Gene**   **ESBL019 Coliform**   **Fold change vs. ESBL019 coliform**   **Description**          
  --------------- ---------- ---------------------- -------------------------------------- ----------------- ------ ---------------------------------------------------------------
  Adhesin         papG       5                      2.4                                    3.0               2.7    PapG protein
                  papF       5                      2.8                                    4.2               2.2    PapF protein
  Growth          carB       7,750                  −2.5                                   −6.0              −2.7   Carbamoyl-phosphate synthase large subunit
  LPS synthesis   waaV       4                      3.0                                    4.3               2.3    Putative beta1.3-glucosyltransferase
                  rfbC       4                      2.9                                    6.5               2.7    dTDP-6-deoxy-D-glucose-3.5 epimerase
  Metabolism      mglB       2,552                  −3.7                                   −10.0             3.5    D-galactose-binding periplasmic protein precursor
  Motility        fliC       5                      2.4                                    3.8               2.2    Flagellar biosynthesis flagellin. filament structural protein
  Protection      tcpC       6                      −4.2                                   −4.1              −2.1   TCP pilus biosynthesis protein tcpC
                  ompT       5,577                  2.5                                    −2.7              −5.2   Protease VII precursor
                  wcaE       13                     3.6                                    31.7              3.2    Putative colanic acid biosynthesis glycosyl transferase
                  ibpA       155                    7.1                                    37.4              4.3    Heat shock protein
                  ibpB       124                    6.0                                    56.6              12.0   Heat shock protein
  Siderophore     sitB       1,841                  −4.5                                   −10.9             −2.8   SitB protein
                  chuT       1,255                  −7.0                                   −9.1              −2.3   Putative Periplasmic binding protein
                  fepE       5,165                  −2.4                                   −5.4              −2.9   Ferric enterobactin transport protein fepE
                  fepA       2,007                  −3.0                                   −3.9              −2.6   Ferrienterobactin receptor precursor
                  iroN       5                      2.6                                    3.5               2.9    Siderophore receptor IroN
                  entF       6                      2.4                                    3.7               2.0    ATP-dependent serine activating enzyme
  Toxins          hlyC       7                      2.8                                    3.7               2.1    Hemolysin C

###### 

Virulence factors associated genes present among significantly altered entities in ESBL019 Transition, ESBL019 Filamented and ESBL019 Reverted compared to ESBL019 Coliform.

  **Function**               **Gene**   **ESBL019 coliform**   **Fold change vs. ESBL019 Coliform**   **Description**                                   
  -------------------------- ---------- ---------------------- -------------------------------------- ----------------- ------------------------------- ----------------------------------------------------------------------------
  Protection                 degP       6,718                  2.1                                                                                      Periplasmic serine protease Do; heat shock protein HtrA
  Siderophore                shiF       344                    −3.0                                                                                     ShiF protein
                             fepC       119                    −2.1                                                                                     ATP-binding component of ferric enterobactin transport
  Toxins                     hlyA       6                      −2.6                                                                                     Hemolysin A
  Growth                     carA       3,789                  −2.2                                   −2.3                                              Carbamoyl-phosphate synthetase. glutamine
  Metabolism                 mglA       801                    −4.5                                   −16.2                                             ATP-bind. comp. of methyl-galactoside transp. and galactose taxis
                             dctA       3,224                  −5.0                                   −8.0                                              Uptake of C4-dicarboxylic acids
  Protection                 ivy        1,292                  3.3                                    4.4                                               orf. hypothetical protein
  Siderophore                entE       763                    −2.3                                   −5.7                                              2.3-dihydroxybenzoate-AMP ligase
                             entC       708                    −2.9                                   −4.3                                              isochorismate hydroxymutase 2. enterochelin biosynthesis
                             iucA       641                    −2.2                                   −2.9                                              IucA protein
                             fepB       269                    −2.2                                   −2.6                                              Ferric enterobactin
                             iroB       10                     2.0                                    2.7                                               Putative glucosyltransferase
                             chuA       595                    −2.0                                   −2.5                                              Outer membrane heme/hemoglobin receptor
  Adhesin                    papX       3,768                                                         −5.5                                              PapX protein
                             focX       6,009                                                         −5.4                                              Putative Regulatory protein
                             csgE       234                                                           −2.5                                              Curli production assembly/transport component. 2nd curli operon
                             flu        796                                                           −2.4                                              Outer membrane fluffing protein. similar to adhesin
                             ompA       145,147                                                       −2.2                                              Outer membrane protein 3a
                             sfaB       40                                                            2.4                                               Putative F1C and S fimbrial switch Regulatory
                             papI       20                                                            2.6                                               PapI protein
                             phoU       1,346                                                         2.7                                               neg. reg. for pho regulon and putative enzyme in phosphate metab.
                             focG       18                                                            2.7                                               F1C minor fimbrial subunit protein G presursor
                             focD       11                                                            2.9                                               F1C fimbrial usher
                             papH       12                                                            3.1                                               PapH protein
                             focC       14                                                            3.1                                               F1C periplasmic chaperone
                             focH       23                                                            3.1                                               F1C Putative fimbrial adhesin precursor
                             csgA       5                                                             3.3                                               Curlin major subunit. coiled surface structures; cryptic
                             focF       14                                                            3.4                                               F1C minor fimbrial subunit F precursor
                             papA       21                                                            3.6                                               PapA protein
                             papK       10                                                            3.7                                               PapK protein
                             papD       1,267                                                         3.9                                               PapD protein
                             papC       9                                                             3.9                                               PapC protein
                             papE       13                                                            4.0                                               PapE protein
                             fimE       351                                                           5.5                                               Recombinase involved in phase variation; regulator for fimA
                             fimB       40                                                            6.8                                               Recombinase involved in phase variation; regulator for fimA
  LPS synthesis              waaI       14                                                            2.2                                               Putative LPS biosynthesis enzyme
                             waaJ       3                                                             2.2                                               Putative LPS biosynthesis enzyme
                             waaL       39                                                            2.5                                               Lipid A-core. surface polymer ligase
                             waaA       105                                                           2.7                                               3-deoxy-D-manno-octulosonic-acid transferase
                             yibD       93                                                            3.2                                               Putative regulator
                             rfbA       23                                                            3.2                                               Glucose-1-phosphate thymidylyltransferase
                             waaY       11                                                            3.8                                               Putative LPS biosynthesis protein
  Metabolism                 dppA       8,306                                                         −8.6                                              Dipeptide transport protein
                             narH       262                                                           −4.1                                              Nitrate reductase 1. beta subunit
                             narG       214                                                           −3.9                                              Nitrate reductase 1. alpha subunit
                             fruR       3,876                                                         −3.3                                              Transcriptional repressor of fru operon and others
                             deoC       1,595                                                         −2.6                                              2-deoxyribose-5-phosphate aldolase
                             malX       201                                                           −2.3                                              PTS system. maltose and glucose-specific II ABC
                             lysR       81                                                            2.1                                               Positive regulator for lys
                             ycjV       10                                                            2.5                                               Putative ATP-binding component of a transport system
                             gatC       88                                                            2.6                                               PTS system galactitol-specific enzyme IIC
                             btuB       147                                                           2.8                                               Outer memb. Rec. for transp. of vit B12. E colicins and bact.phage
                             wbdP       3                                                             3.0                                               Glycosyl transferase
                             ycfQ       354                                                           3.2                                               orf. hypothetical protein
                             yedL       5                                                             3.6                                               orf. hypothetical protein
                             ycjM       69                                                            8.6                                               Putative sucrose phosphorylase
  Motility                   flhD       638                                                           −5.6                                              reg. of flag. biosynth. acting on class 2 operons; transcrip. Init. factor
                             flhC       365                                                           −3.5                                              reg. of flag. Biosynth. acting on class 2 operons; transcrip. Init. factor
                             fliY       3,253                                                         −2.5                                              Putative periplasmic binding transport protein
                             flgM       281                                                           −2.1                                              Anti-FliA
                             fliG       22                                                            2.1                                               flag. biosynth. component of motor switching and energizing
                             fliZ       156                                                           2.2                                               orf. hypothetical protein
                             flhE       8                                                             2.2                                               Flagellar protein
                             flgA       134                                                           2.4                                               Flagellar biosynthesis; assembly of basal-body periplasmic P ring
                             fliD       17                                                            2.5                                               Flag. biosynth; filament capping protein; enables filament assembly
                             fliI       39                                                            2.5                                               Flagellum-specific ATP synthase
                             fliK       168                                                           3.4                                               Flagellar hook-length control protein
  Protection                 ompF       45,769                                                        −7.3                                              Outer membrane protein 1a
                             kdpE       132                                                           2.1                                               Regulator of kdp operon
                             sbmA       231                                                           2.1                                               Sensitivity to microcin B17. possibly envelop protein
                             gfcC       9                                                             2.3                                               orf. hypothetical protein
                             sdiA       295                                                           2.5                                               Regulatory protein sdiA
                             etk        23                                                            2.7                                               orf. hypothetical protein
                             etp        26                                                            2.7                                               Putative phosphatase
                             yadK       10                                                            2.7                                               Protein yadK
                             ybcL       84                                                            3.0                                               Protein ybcL precursor
                             gfcE       10                                                            3.1                                               Putative function in exopolysaccharide production
                             gfcD       553                                                           3.9                                               orf. hypothetical protein
                             ycbQ       8                                                             4.3                                               Putative fimbrial-like protein
                             gfcA       278                                                           4.6                                               orf. hypothetical protein
                             sulA       2,130                                                         5.4                                               Suppressor of lon; inhibits cell division and ftsZ ring formation
                             recA       1,662                                                         6.0                                               DNA strand exchange and renaturation. DNA-dep ATPase
                             lexA       489                                                           6.3                                               Regulator for SOS
                             bhsA       241                                                           8.8                                               orf. hypothetical protein
  Secretion                  tir        39                                                            2.2                                               Putative translocated intimin receptor protein
                             escJ       15                                                            2.5                                               escJ
                             escN       15                                                            2.8                                               escN
                             espB       8                                                             2.8                                               Secreted protein EspB
                             sepQ       3                                                             3.1                                               sepQ
                             sepZ       11                                                            3.3                                               sepZ
                             eae        20                                                            3.4                                               Intimin adherence protein
                             escU       49                                                            3.6                                               escU
  Siderophore                entB       345                                                           −3.6                                              2.3-dihydro-2.3-dihydroxybenzoate synthetase. isochroismatase
                             entF       6                                                             −3.5                                              Enterobactin synthetase component F
                             iucC       867                                                           −3.5                                              IucC protein
                             entA       262                                                           −3.4                                              2.3-dihydro-2.3-dihydroxybenzoate dehydrogenase
                             chuS       655                                                           −2.8                                              Putative heme/hemoglobin transport protein
                             fepG       967                                                           −2.7                                              Ferric enterobactin transport protein
                             iucB       365                                                           −2.6                                              IucB protein
                             feoB       937                                                           −2.5                                              Ferrous iron transport protein B
                             iroE       10                                                            3.7                                               IroE protein
  Toxins                     stx1A      22                                                            2.3                                               Shiga-like toxin 1 subunit A encoded within
                             hlyE       135                                                           2.8                                               Hemolysin E
                             stx2B      6                                                             3.6                                               Shiga-like toxin II B subunit
                             stx1B      12                                                            4.3                                               Shiga-like toxin 1 subunit B
  Transcription regulation   rfaH       384                                                           2.1                                               Transcription act. of lipopolysaccharide core. F pilin. and haemolysin
  Adhesin                    fimC       26                                                            2.1               3.5                             Periplasmic chaperone. required for type 1 fimbriae
                             fimI       39                                                            2.1               3.4                             Fimbrial protein
                             fimH       36                                                            2.1               3.6                             Minor fimbrial subunit. D-mannose specific adhesin
                             fimD       25                                                            2.2               2.9                             Outer membrane protein; export and assembly of type 1 fimbriae
                             fimA       126                                                           2.0               2.3                             Major type 1 subunit fimbrin
                             csgC       19                                                            2.6               2.0                             Putative curli production protein
                             fimG       27                                                            2.8               2.5                             Fimbrial morphology
                             fimF       8                                                             3.6               3.3                             FimF protein precursor
  LPS synthesis              yijP       4,354                                                         −2.3              −3.8                            Protein yijP
  Metabolism                 glnA       8,617                                                         −86.0             −15.1                           Glutamine synthetase
                             ilvD       3,921                                                         −11.3             −8.2                            Dihydroxy-acid dehydratase
                             serA       2,494                                                         −9.6              −3.7                            D-3-phosphoglycerate dehydrogenase
                             tdcE       123                                                           −3.6              3.7                             Keto-acid formate acetyltransferase
                             trpB       573                                                           −3.0              −2.5                            Tryptophan synthase. beta protein
                             kbaZ       9                                                             2.3               16.0                            Putative tagatose 6-phosphate kinase 2
                             pitB       26                                                            2.8               3.2                             Low-affinity phosphate transport
                             aer        29                                                            2.8               3.3                             Aerotaxis sensor receptor. flavoprotein
                             trxC       276                                                           3.5               3.3                             Thioredoxin 2
  Motility                   fliJ       13                                                            3.4               2.3                             Flagellar fliJ protein
  Protection                 ompW       4,714                                                         −9.1              2.6                             Outer membrane protein W precursor
                             matB       614                                                           −2.5              2.2                             orf. hypothetical protein
                             evgS       526                                                           −2.2              −2.9                            Putative sensor for regulator EvgA
                             ECs0850    5                                                             4.6               2.2                             Hypothetical protein
                             manB       11                                                            8.5               2.3                             Phosphomannomutase
  Siderophore                yjjQ       68                                                            2.1               2.4                             putative regulator
  Transcription regulation   rpoB       12,927                                                        −2.3              −4.5                            RNA polymerase. beta subunit
  rpoA                       68,440                            −2.3                                   −3.7              RNA polymerase. alpha subunit   
  Adhesin                    ppdD       21                                                                              2.3                             Prelipin peptidase dependent protein
  LPS synthesis              rfaS       12,88                                                                           −4.3                            Lipopolysaccharide core biosynthesis
                             rfaP       3,909                                                                           −3.8                            LPS core biosynthesis; phosphorylation of core heptose
                             rfaZ       2,091                                                                           −3.0                            Lipopolysaccharide core biosynthesis
                             rfaY       1,690                                                                           −2.5                            Lipopolysaccharide core biosynthesis
                             waaU       999                                                                             −2.1                            Probably hexose transferase; lipopolysaccharide core biosynthesis
                             rfaG       1,009                                                                           −2.0                            Lipopolysaccharide core biosynthesis protein rfaG
  Metabolism                 eda        3,246                                                                           −3.1                            2-keto-3-deoxygluc 6-phos aldo and 2-keto-4-hydroxyglut aldo
                             tktA       2,823                                                                           −2.2                            Transketolase 1 isozyme
                             dsbA       27,226                                                                          −2.1                            Protein disulfide isomerase I. essential for cytochrome c synthesis
                             prfB       3,054                                                                           −2.0                            Peptide chain release factor 2
                             gnsA       3,461                                                                           −2.0                            Predicted regulator of phosphatidylethanolamine synthesis
                             yjhS       37                                                                              2.1                             orf. hypothetical protein
                             agaA       113                                                                             2.5                             Putative N-acetylgalactosamine-6-phosphate deacetylase
                             agaC       42                                                                              2.7                             PTS system N-acetylgalactosamine-specific IIC component 1
                             dctA       3,224                                                                           3.2                             Uptake of C4-dicarboxylic acids
                             astA       93                                                                              3.6                             orf. hypothetical protein
                             lacZ       20                                                                              3.7                             Beta-galactosidase
                             gatZ       18                                                                              4.1                             Putative tagatose 6-phosphate kinase 1
                             gatB       15                                                                              5.0                             Galactitol-specific enzyme IIB of phosphotransferase system
                             agaS       72                                                                              5.3                             Putative tagatose-6-phosphate aldose/ketose isomerase
                             agaB       32                                                                              7.0                             PTS system. cytopl. N-acetylgalactosamine-spec IIB component 1
                             ulaB       27                                                                              7.2                             Putative transport protein
                             ulaC       86                                                                              8.6                             Putative PTS system enzyme II A component
                             ulaA       76                                                                              11.2                            orf. hypothetical protein
                             agaW       40                                                                              18.1                            PTS system N-acetylgalactosameine-specific IIC component 2
                             agaV       19                                                                              18.9                            PTS system. cytopl. N-acetylgalactosamine-spec IIB component 2
                             kbaY       19                                                                              28.0                            Tagatose-bisphosphate aldolase 2
  Motility                   fliT       31                                                                              2.1                             Flagellar biosynthesis; repressor of class 3a and 3b operons
                             flgJ       29                                                                              2.1                             Flagellar biosynthesis
                             fliO       11                                                                              2.1                             Flagellar protein fliO
                             fliL       23                                                                              2.2                             Flagellar biosynthesis
                             flgH       20                                                                              2.2                             Flagellar biosynthesis. basal-body outer-membrane L
                             flhB       38                                                                              2.3                             Putative part of export apparatus for flagellar proteins
                             flgB       24                                                                              2.3                             Flagellar biosynthesis. cell-proximal portion of basal-body rod
                             fliE       37                                                                              2.7                             Flagellar biosynthesis; basal-body component
                             fliF       27                                                                              2.8                             Flagellar biosynthesis; basal-body MS
                             lfhA       8                                                                               3.1                             Flagellar biosynthesis
                             fliP       11                                                                              3.3                             Flagellar biosynthetic protein fliP precursor
                             fliQ       21                                                                              4.9                             Flagellar biosynthesis
  Protection                 kpsC       986                                                                             −3.4                            KpsC protein
                             bamA       6,961                                                                           −3.3                            orf. hypothetical protein
                             evgS       526                                                                             −2.9                            putative sensor for regulator EvgA
                             degP       6,718                                                                           −2.6                            Periplasmic serine protease Do; heat shock protein HtrA
                             kpsM       3,290                                                                           −2.2                            KpsM protein
  Transcription regulation   fis        61,722                                                                          −3.9                            Site-specific DNA inversion stimulation factor; DNA-binding protein

In order to confirm the microarray results, real-time qPCR was carried out on seven genes belonging to the functional categories Adhesion (*FimAH*), Protection (*ibpAB*), and Siderophore (*chuAT, sitB*) that were significantly altered compared to ESBL019 Coliform. In agreement with the microarray, a significant upregulation of *FimAH* was observed in ESBL019 Filamented and ESBL019 Reverted state compared to ESBL019 Coliform (Table [2](#T2){ref-type="table"}). In addition, *ibpAB* was observed to be significant upregulated in all the three different states compared to ESBL019 Coliform, as shown by the microarray data. We also found that *chuAT, sitB* were significantly downregulated in ESBL019 Transition and ESBL019 Filamented state compared to ESBL019 Coliform (Table [2](#T2){ref-type="table"}). However, this was not observed to be true for the ESBL019 Reverted state.

###### 

Quantitative real-time PCR data for ESBL019 Transition, ESBL019 Filamented and ESBL019 Reverted compared to ESBL019 Coliform.

  **Gene**                                                 **Fold change vs. ESBL019 coliform**         **Description**                             
  ---------- --------------------------------------------- -------------------------------------------- ------------------------------------------- ----------------------------------------------------
  FimA       −1.2 ± 0.86[^a^](#TN1){ref-type="table-fn"}   15 ± 3.1[^a^](#TN1){ref-type="table-fn"}     8.5 ± 2.1[^a^](#TN1){ref-type="table-fn"}   Major type 1 subunit fimbrin
  FimH       −1.1 ± 0.74[^a^](#TN1){ref-type="table-fn"}   10 ± 1.8[^a^](#TN1){ref-type="table-fn"}     11 ± 2.3[^a^](#TN1){ref-type="table-fn"}    Minor fimbrial subunit. D-mannose specific adhesin
  ibpA       5.3 ± 0.90[^a^](#TN1){ref-type="table-fn"}    230 ± 49[^a^](#TN1){ref-type="table-fn"}     22 ± 3.7[^a^](#TN1){ref-type="table-fn"}    Heat shock protein
  ibpB       7.2 ± 1.5[^a^](#TN1){ref-type="table-fn"}     330 ± 80[^a^](#TN1){ref-type="table-fn"}     130 ± 33[^a^](#TN1){ref-type="table-fn"}    Heat shock protein
  chuA       −6.3 ± 1.2[^a^](#TN1){ref-type="table-fn"}    −1.6 ± 0.1[^a^](#TN1){ref-type="table-fn"}   0.90 ± 1.0                                  Putative Periplasmic binding protein
  chuT       −15 ± 3.2[^a^](#TN1){ref-type="table-fn"}     −4.4 ± 1.5[^a^](#TN1){ref-type="table-fn"}   1.1 ± 1.0                                   Outer membrane heme/hemoglobin receptor
  sitB       −11 ± 1.6[^a^](#TN1){ref-type="table-fn"}     −5.4 ± 1.6[^a^](#TN1){ref-type="table-fn"}   0.71 ± 0.82                                 SitB protein

*n = 3--4*.

*Significantly altered genes compared to ESBL019 Coliform*.

Fimbriae agglutination
----------------------

We proceeded with evaluating the phenotypical presence and functionality of the type-1 fimbriae and P-fimbriae in the different morphological states of ESBL019. Yeast agglutination confirmed that all the morphological states of ESBL019 expressed functional type-1 fimbriae (Figures [4B--E](#F4){ref-type="fig"}) compared to only yeast (Figure [4A](#F4){ref-type="fig"}). The aggregation pattern between the rod shaped (ESBL019 Coliform and ESBL019 Reverted) and the elongated ESBL019 (ESBL019 Transition and ESBL019 Filamented) morphologies were strikingly different. The yeast was bound along the elongated bacteria and gave a more uniform aggregation (Figures [4C,D](#F4){ref-type="fig"}), while the rod shaped bacteria formed large isolated yeast aggregates (Figures [4B,E](#F4){ref-type="fig"}). Human Erythrocytes of blood group P were used to evaluate the P-fimbriae expression. All the morphological states of ESBL019 expressed functional P-fimbriae (Figures [4G--J](#F4){ref-type="fig"}) compared to only erythrocytes (Figure [4F](#F4){ref-type="fig"}). We also observed an increased aggregation by the ESBL019 Transition (Figure [4H](#F4){ref-type="fig"}), ESBL019 Filamented (Figure [4I](#F4){ref-type="fig"}) and ESBL019 Reverted (Figure [4J](#F4){ref-type="fig"}) states compared to ESBL019 Coliform (Figure [4G](#F4){ref-type="fig"}).

![Fimbriae aggregation and TNF-α release from HBEP cells infected with the different morphologies of ESBL019. Type-1 fimbriae functionality was assessed by yeast agglutination without **(A)** or with ESBL019 Coliform **(B)**, ESBL019 Transition **(C)**, ESBL019 Filamented **(D)** and ESBL019 Reverted **(E)** using light microscopy. P-fimbriae functionality was assessed by P-positive human erythrocyte agglutination without **(F)** or with ESBL019 Coliform **(G)**, ESBL019 Transition **(H)**, ESBL019 Filamented **(I)**, and ESBL019 Reverted **(J)** using light microscopy. Scale bare: 200 μm. TNF-α release from HBEP cells stimulated with ESBL019 Coliform, ESBL019 Transition, ESBL019 Filamented and ESBL019 Reverted (MOI10) for 4 h in the presence (Transition, Filamented) or absence (Coliform and Reverted) of ceftibuten **(K)**. Data are presented as mean ± SEM of *n* = 4 independent experiments. Asterisks denote statistical significance ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001.](fmicb-08-01058-g0004){#F4}

Epithelial TNF-α release evoked by the different morphological states
---------------------------------------------------------------------

Primary human bladder epithelial cells were stimulated with the different morphological states of ESBL019 to determine their ability to induce the pro-inflammatory cytokine TNF-α. The unstimulated control cells showed no basal release of TNF-α (Figure [4K](#F4){ref-type="fig"}). ESBL019 Coliform and ESBL Filamented were able to induce an increased release of TNF-α compared to the control. ESBL019 Transition induced a significant higher release of TNF-α compared to control (*p* \< 0.001), ESBL019 Coliform (*p* \< 0.01), ESBL019 Filamented (*p* \< 0.01) and ESBL019 Reverted (*p* \< 0.001). In contrast to the other morphological states of ESBL019, ESBL019 Reverted did not induce any release of TNF-α from the bladder epithelial cells. Taken together, the different morphological states of ESBL019 induce a diverse TNF-α release from bladder epithelial cells.

Discussion {#s4}
==========

Global gene expression profiling of the different morphological states of ESBL019 demonstrated a significant transcriptional alteration of a large number of genes. In the ESBL019 Transition state, close to 7% of the entities on the array were altered, 32% for ESBL019 Filamented and 19% for ESBL019 Reverted. Thus, it appears that the morphological plasticity of UPEC is associated with an extensive flux in the transcriptome of the bacteria and especially in the filamented state. To the best of our knowledge, this is the first study that investigates changes in global gene expression patterns and in virulence factor associated genes in ESBL-producing UPEC during the morphologic transitions induced by ineffective antibiotics. Importantly, all experiments were conducted in the presence of human primary bladder epithelial cells to mimic the *in vivo* host-pathogen interactions in a physiologically relevant manner.

The majority of the identified changes in gene ontologies and pathways were associated with metabolic functions. Many metabolic functions are not specific for pathogens and their role in infection fitness remains therefore more or less unexplored (Subashchandrabose and Mobley, [@B35]). In the ESBL019 Transition state, we observed that genes associated with the tricarboxylic acid cycle (TCA) and glucogenic amino acid (arginine, glutamate, glutamine, and proline) metabolism were in majority downregulated. We also found that the gene *dctA*, which encodes for the C4-dicarboxylate transporter that is responsible for the uptake of fumarate, succinate and malate was downregulated. Previous studies have shown that gluconeogenesis and the TCA cycle, but not Entner-Doudoroff, glycolysis or pentose-phosphate pathways are important for the fitness of UPEC during *in vivo* experimental UTI (Alteri et al., [@B1]). Genes associated with amino acid metabolism, such as *dctA, serA* (L-serine biosynthesis), *ilvD* (isoleucine and valine biosynthesis), *trpB* (tryptophan synthase beta), *glnA* (catalyzing conversion of glutamate to glutamine) and *dppA* (dipeptide transporter) were observed to be downregulated in the ESBL019 Filamented state. It has been shown that UPEC grown in urine utilizes primarily peptides and amino acids as carbon sources instead of glucose (Alteri et al., [@B1]). We also observed that several sugar transporter associated genes such as *gatC* and *ycjV* were upregulated in the filamented state, which could lead to an increased acquisition of carbon sources. In the ESBL019 Reverted state, glucose and xylose degradation, glycolysis, Entner-Doudoroff, NAD biosynthesis and gluconeogenesis pathways were downregulated. We also found, in accordance with the filamented state, that *glnA, ilvD*, and *serA* were downregulated. In addition, an increase in genes associated with replenishing TCA cycle intermediates (*dctA* and *astA*), sugar transporters (*agaABCVW*), L-ascorbate transport (*ulaABC*) and degradation of other carbon sources like lactose (l*acZ*) was observed. It has recently been shown that beta-galactosidase (l*acZ*) may play an important role in intracellular UPEC growth and IBC maturation (Conover et al., [@B10]). An interesting finding in the ESBL019 Reverted state was the downregulation of genes associated with transcription, translation, ribosome biosynthesis and tRNA charging. Taken together, these data demonstrates that all three morphological states of UPEC are associated with a decreased energy-yielding cell metabolism, suggesting that survival rather than growth is prioritized. Knowledge of these metabolic shifts could contribute to finding new therapeutic targets to limit the bacteria\'s ability to acquire alternative carbon sources.

Metals such as iron are essential for bacterial life and the low concentration of soluble iron in the urinary tract is regarded as a limiting factor for UPEC growth (Roos et al., [@B30]). Consequently, it has been shown that iron acquisition is important for UPEC survival and pathogenicity (Subashchandrabose and Mobley, [@B35]). UPEC can acquire iron through several mechanisms such as siderophores (ferric iron chelators), ferrous iron transporters and heme through outer membrane receptors (Cho et al., [@B9]). We observed that the iron acquisition systems in all the morphological states of UPEC changed significantly. Genes involved in the enterobactin system (*entABF, fepABE*), heme system (*chuST*) and ferrous iron uptake (*sitB*) were downregulated in all the three morphological states. However, genes in the aerobactin system (*iucAC*) were downregulated in the ESBL019 Transition and ESBL019 Filamented state but not in the ESBL019 Reverted state. The salmochelin siderophore system (*iroEN*) was upregulated in all the three morphological states. qPCR analysis confirmed that *chuAT* and *sitB* were significantly downregulated in ESBL019 Transition and ESBL019 Filamented state, but not in the ESBL019 Reverted state compared to ESBL019 Coliform. The iron acquisition systems in UPEC have been demonstrated to be redundant, but individual systems have been shown to play key roles in fitness and pathogenicity in different regions of the urinary tract (Garcia et al., [@B16]). Aerobactin receptors have been shown to significantly contribute to *in vivo* fitness and they are critical for UPEC virulence (Garcia et al., [@B16]). It was recently shown that the virulence associated with iron acquisition could be partially due to modulation of amino acid metabolism (Su et al., [@B33]). Taken together, these data show that the iron acquisition systems in UPEC are altered during morphological shifts, mainly downregulated, but the redundancy in the systems may contribute to preserving *in vivo* fitness. In addition, the lack of change in the aerobactin system, one of the key siderophores system in uropathogenicity, may indicate that the reverted morphology maintains virulence in the life cycle of UPEC.

During colonization of the urinary tract, UPEC utilizes different adhesion molecules (like fimbriae) to adhere and invade the epithelial cells in order to persist in the urinary tract (Subashchandrabose and Mobley, [@B35]). The P-fimbriae encoding genes (*pap*) were upregulated in all the three different morphological states of ESBL019 and we also observed an increased phenotypic expression by agglutination in all the different morphological states compared to ESBL019 Coliform. The P-fimbriae is associated with the pathogenicity of ascending UTI and pyelonephritis (Frendeus et al., [@B15]). The type-1 fimbriae associated genes (*fim*), which play an important role in adhesion, invasion, IBC, and biofilm formation during cystitis (Flores-Mireles et al., [@B13]) were upregulated in ESBL019 Filamented and ESBL019 Reverted, but no changes were observed in ESBL019 Transition state. Consistent with the microarray data, *fimAH* were markedly upregulated in the Filamented and Reverted state based on qPCR data. We confirmed phenotypically functional type-1 fimbriae in all the different states by yeast agglutination assays. This indicates that the morphological plasticity of UPEC does not compromise on adhesion factors important for colonizing the urinary tract. We hypothesize that the observed upregulation of P-and type-1 fimbriae associated genes is a mechanism to persist in the urinary tract especially after the bacteria emerge from the IBC in a filamented form. Taken together, our results show that all UPEC morphologies maintain fimbrial expression, which could promote persistence and colonization of the urinary tract.

Ascendance from the bladder to the kidneys is an important virulence trait of UPEC associated with motility and flagella expression (Pichon et al., [@B27]). Studies of morphological plasticity of ESBL019 showed only one significantly upregulated flagellin gene in the ESBL019 Transition state (*fliC*), but many flagellin genes were both up-and downregulated in the ESBL019 Filamented state. In the ESBL019 Reverted state, all the significantly altered genes were upregulated. These results indicate that morphological plasticity is associated with altered flagellin gene expression, but additional functional experiments are needed to assess the effects on motility.

We and others have shown that filamentation of *E. coli* is associated with a rapid production and release of endotoxins (Gould and MacKenzie, [@B17]; Demirel et al., [@B12]). Genes associated with LPS biosynthesis were almost unchanged in the ESBL019 Transition state, but all LPS genes were upregulated in the ESBL019 Filamented state. However, the majority of the LPS associated genes were downregulated in the ESBL019 Reverted state. The modulation of LPS synthesis during the morphological shifts could be a compensation mechanism to replenish LPS on the surface of ESBL019, as increased shedding of LPS was observed during the transition state (Demirel et al., [@B12]). This modulation of LPS could play a part in the pathogenicity of UPEC as LPS modulates pro-inflammatory responses (Bussolati et al., [@B8]).

The morphological plasticity of ESBL019 showed an alteration in many genes associated with bacterial protection. Genes like *tcpC*, which is associated with inhibition of pro-inflammatory responses (Yadav et al., [@B38]), was downregulated in all three states. We also observed that the gene encoding for the outer membrane protein *ompT*, which is involved in the resistance of different antimicrobial peptides (Brannon et al., [@B6]), was upregulated in the transition state, but downregulated in the two other states. The gene encoding ompF, which is a porin for antibiotics, was downregulated in the filamented state and this has been associated with increased antibiotic resistance (Kishii and Takei, [@B23]). OmpW, which is required for UPECs resistance against phagocytosis (Wu et al., [@B37]) was downregulated in the filamented state, but upregulated in the reverted state. We have previously shown that filamented UPEC can be successfully phagocytized by neutrophils (Demirel et al., [@B12]). Related to neutrophil immunity, the *ybcL* gene proposed to inhibit neutrophil migration was upregulated in the ESBL019 Filamented state (Lau et al., [@B24]). The gene ontology SOS response was enriched in the ESBL019 Filamented state and the associated genes *recA, lexA*, and *sulA* were upregulated. The SOS system is a response to DNA damage and inhibits cell division and septa formation in order to repair the DNA damage (Justice et al., [@B20]). *sulA* has been shown to mediate UPEC filamentation and this filamentation is associated with increased genetic variability and point mutations that can lead to antibiotic resistance (Bos et al., [@B4]). The filamented form also showed an upregulation of genes (*tir, esc*, and *sep*) encoding the Type 3 secretion system (T3SS), which is used by bacteria to inject effectors directly into host cell (Subashchandrabose and Mobley, [@B35]). T3SS genes are traditionally not found in UPEC, but they have recently been reported to be found in some UPEC isolates (Subashchandrabose et al., [@B34]), although the role during UTI remains to be determined.

We continued with analyzing the TNF-α production from primary bladder epithelial cells induced by the different morphological states. This was done in order to evaluate the biological relevance of the microarray data. The ESBL019 Transition state induced a significant increase in TNF-α production compared to the control and the other morphologies. We have previously shown that the transition state is associated with increased LPS and ATP release, both known to induce pro-inflammatory cytokines from uroepithelial cells (Demirel et al., [@B12]). The reverted state did not induce TNF-α production and this may give the reverted UPEC an advantage in colonizing the bladder as host cytokine responses are essential for attracting neutrophils (Smart and Casale, [@B32]). However, it remains to be investigated if the lack of immune activation by the reverted state is due to an inability to induce an immune response or to an active immune suppression. Our agglutination assays showed no reduced fimbriae function to support that the reverted state is unable to induce an immune response. However, several interesting findings, like the downregulation of LPS associated genes in the reverted state, remains to be evaluated.

Together, these results provide insight into the global gene expression patterns of the different morphological states of ESBL019 induced by an ineffective antibiotic. The decreased energy-yielding metabolism and up-regulated adhesion, suggest that survival and persistence in the bladder is priority rather than growth during the morphological plasticity of ESBL-producing UPEC. These findings are also strengthened by the fact that the reverted state did not induce TNF-α release, which gives the bacteria an advantage in colonizing the bladder. Understanding how ineffective antibiotic treatments affect the virulence and metabolism of ESBL-producing UPEC can promote the identification of new therapeutic targets and new adjuvant combination treatments to reduce the prevalence of multiresistant bacteria.
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